1Ishida Y, Kondo T, Tsuneyama K, et al. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice[J]. J Leukoc Biol, 2004, 75(1): 59-67.
2Lombard C, McKalhp R J, Hylemon PB, et al. Fas Ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver[J]. Clin Immunol, 2003, 109(2) : 144 - 153.
3Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immuniuty, 1995, 3(6) :673 - 682.
4Miyashita T, Kawakami A, Nakashima T, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)-mediated apoptosis of fibroblast-like synovial cells[J]. Clin Exp Immunol, 2004, 137(2) :430- 436.
5Zhang XD, Zhang XY, Gray CP, et al. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria[J]. Cancer Res, 2001, 61(19):7339-7348.
6Chen X, Thakkar H, Tyan F, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer[J]. Oncogene, 2001, 20(42): 6373-6083.
7Coke R, Coke A, Coke B, et al. Regulation of TRAIL-in-duced apoptosis by transcription factors[J]. Cell Immunol,2000, 201(2):77 - 82.
8Takeda K, Smyth MJ, Cremey E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development[J]. J Exp Med, 2002, 195(2) : 161 - 169.
9Kamohara H, Matsuyama W, Shimozato O, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils[J]. Immunology, 2004, 111(2):186- 194.
10Komdeur R, Meijer C, Van Zweeden M, et al. Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells[J].Int J Oncol , 2004, 25(3) :677 - 684.
